Convegno su rischio biologico e bioterrorismo

[rossana at comodinoposta.org]

A Roma si è tenuto un Convegno su rischio biologico e bioterrorismo, 
sarà interessante sapere cosa si son detti.
http://www.uniroma1.it/eventi/ricerca/bioterrorissmo.php

Ma di cosa si sta occupando ultimamente l'America per quanto riguarda il 
bioterrorismo?

Vi metto un pò di link per chi volesse saperne di più. Si può dire 
subito che si sta occupando della febbre emorragica (che include anche 
il virus di Ebola). Ma chi e come?
Il chi lo vedrete nei link mentre per quanto riguarda il come si possono 
indicare due diversi approcci: quello di AVI BioPharma studiato in 
collaborazione con U.S. Army Medical Research Institute of Infectious 
Diseases, che riguarda il composto antisenso NeuGene, e quello che ha 
ripreso lo studio dei Nobel 2006 per la medici Andrew Z. Fire e Craig C. 
Mello per la scoperta del meccanismo dell’RNA “interferenza”, della 
Functional Genetics e Alnylam Pharmaceuticals

Ovviamente si parla di milioni e milioni di dollari.

http://www.dtra.mil/

PORTLAND- AVI BioPharma, Inc. today announced publication of significant 
research carried out in collaboration with the U.S. Army Medical 
Research Institute of Infectious Diseases (USAMRIID USAMRIID - United 
States Army Medical Research Institute of Infectious Diseases (US DoD)
The report, published today in Public Library of Science (PLoS) 
Pathogens, a peer-reviewed monthly journal published by the Public 
Library of Science, demonstrates success using AVI's proprietary 
NEUGENE(R) antisense technology as a countermeasure to Ebola virus Ebola 
virus (ēbō`lə), a member of a family (Filovirus) of viruses that cause 
hemorrhagic fevers. The virus, named for the region in Congo (Kinshasa) 
where it was first identified in 1976, emerged from the rain forest, 
where it survives in as yet unconfirmed hosts, possibly several species 
of fruit bats.

http://www.avibio.com/neugene_antisense.php
http://www.usamriid.army.mil/

Functional Genetics grabs $6.5M, considers selling
http://washington.bizjournals.com/washington/stories/2007/05/21/story15.html
http://www.functional-genetics.com/FGI_Main/Welcome.html

Alnylam Biodefense was established to build a robust platform for 
developing RNAi therapeutics targeting threats of bioterrorism. Funding 
for the company's Ebola virus, pandemic flu, and viral hemorrhagic fever 
programs represents an example of broad public health and federal 
interest in the potential of RNAi technology to treat and prevent 
disease from these, and other serious and life-threatening viruses.
http://www.alnylam.com/therapeutic-programs/programs.asp